Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East

Riad El Fakih; Alfadil Haroon; Feras Alfraih; Murtadha K. Al-Khabori; Mohsen Alzahrani; Ahmad Alhuraiji; Abdulaziz Hamadah; Naif I. AlJohani; Bader Alahmari; Mohammed F. Essa; Ibraheem H. Motabi; Imran K. Tailor; Reem S. Almaghrabi; Khalil Al-Farsi; Ibraheem Abosoudah; Mouhab Ayas; Tusneem A. Elhassan; Ashraf M. Suhebeh; Syed Osman Ahmed; Saud Alhayli; Panayotis Kaloyannidis; Ahmad Alsaeed; Khalid Al Anezi; Sameer Alamoudi; Moussab Damlaj; Hani Al Hashmi; Mahmoud Aljurf

doi:10.1038/s41409-021-01312-y

Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East

Riad El Fakih^*, Alfadil Haroon, Feras Alfraih, Murtadha K. Al-Khabori, Mohsen Alzahrani, Ahmad Alhuraiji, Abdulaziz Hamadah, Naif I. AlJohani, Bader Alahmari, Mohammed F. Essa, Ibraheem H. Motabi, Imran K. Tailor, Reem S. Almaghrabi, Khalil Al-Farsi, Ibraheem Abosoudah, Mouhab Ayas, Tusneem A. Elhassan, Ashraf M. Suhebeh, Syed Osman Ahmed, Saud AlhayliPanayotis Kaloyannidis, Ahmad Alsaeed, Khalid Al Anezi, Sameer Alamoudi, Moussab Damlaj, Hani Al Hashmi, Mahmoud Aljurf

^*Corresponding author for this work

Haematology

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

The coronavirus disease‐2019 (COVID‐19) caused by SARS Coronavirus 2 (SARS‐CoV‐2) is a potentially lethal infection. Cancer patients, and specifically hematopoietic cell transplant (HCT) recipients are severely immunocompromised and may be at a higher risk of a complicated course with this infection. We aimed to study the COVID-19 outcomes and severity in post HCT patients. We retrospectively reviewed post-HCT patients diagnosed with COVID-19 between March 15, 2020, and December 1, 2020 at 10 transplant centers across the Middle East. We identified 91 patients with confirmed SARS-CoV-2 infection across 10 transplant centers. The median age upon presentation with COVID-19 was 35. Fifty two patients were post allo-HCT while the remaining 39 patients were post auto-HCT. The median time from transplant was 14.9 months. Mortality rate was 4.4%. Hospital admission rate was 53%. ICU admission rate was 14%. Mechanical ventilation rate was 10%. Oxygen supplementation rate was 18%. Time from HCT to COVID-19 >6 months was associated with lower admission rates and lower rates of the “severity” composite endpoint. Antibody responses was seen 67% of evaluable patients. In this series of HCT recipients, we report overall favorable clinical outcomes for patients with COVID-19 and provide preliminary insights into the clinical course of this disease in this specific population.

Original language	English
Pages (from-to)	2144-2151
Number of pages	8
Journal	Bone Marrow Transplantation
Volume	56
Issue number	9
DOIs	https://doi.org/10.1038/s41409-021-01312-y https://doi.org/10.1038/s41409-021-01312-y
Publication status	Published - Sept 1 2021

ASJC Scopus subject areas

Hematology
Transplantation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Cite this

El Fakih, R., Haroon, A., Alfraih, F., Al-Khabori, M. K., Alzahrani, M., Alhuraiji, A., Hamadah, A., AlJohani, N. I., Alahmari, B., Essa, M. F., Motabi, I. H., Tailor, I. K., Almaghrabi, R. S., Al-Farsi, K., Abosoudah, I., Ayas, M., Elhassan, T. A., Suhebeh, A. M., Ahmed, S. O., ... Aljurf, M. (2021). Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East. Bone Marrow Transplantation, 56(9), 2144-2151. https://doi.org/10.1038/s41409-021-01312-y, https://doi.org/10.1038/s41409-021-01312-y

El Fakih, R, Haroon, A, Alfraih, F, Al-Khabori, MK, Alzahrani, M, Alhuraiji, A, Hamadah, A, AlJohani, NI, Alahmari, B, Essa, MF, Motabi, IH, Tailor, IK, Almaghrabi, RS, Al-Farsi, K, Abosoudah, I, Ayas, M, Elhassan, TA, Suhebeh, AM, Ahmed, SO, Alhayli, S, Kaloyannidis, P, Alsaeed, A, Anezi, KA, Alamoudi, S, Damlaj, M, Hashmi, HA & Aljurf, M 2021, 'Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East', Bone Marrow Transplantation, vol. 56, no. 9, pp. 2144-2151. https://doi.org/10.1038/s41409-021-01312-y, https://doi.org/10.1038/s41409-021-01312-y

@article{bbd02ac8cfb7449cadacf76d66239b92,

title = "Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East",

abstract = "The coronavirus disease‐2019 (COVID‐19) caused by SARS Coronavirus 2 (SARS‐CoV‐2) is a potentially lethal infection. Cancer patients, and specifically hematopoietic cell transplant (HCT) recipients are severely immunocompromised and may be at a higher risk of a complicated course with this infection. We aimed to study the COVID-19 outcomes and severity in post HCT patients. We retrospectively reviewed post-HCT patients diagnosed with COVID-19 between March 15, 2020, and December 1, 2020 at 10 transplant centers across the Middle East. We identified 91 patients with confirmed SARS-CoV-2 infection across 10 transplant centers. The median age upon presentation with COVID-19 was 35. Fifty two patients were post allo-HCT while the remaining 39 patients were post auto-HCT. The median time from transplant was 14.9 months. Mortality rate was 4.4%. Hospital admission rate was 53%. ICU admission rate was 14%. Mechanical ventilation rate was 10%. Oxygen supplementation rate was 18%. Time from HCT to COVID-19 >6 months was associated with lower admission rates and lower rates of the “severity” composite endpoint. Antibody responses was seen 67% of evaluable patients. In this series of HCT recipients, we report overall favorable clinical outcomes for patients with COVID-19 and provide preliminary insights into the clinical course of this disease in this specific population.",

author = "{El Fakih}, Riad and Alfadil Haroon and Feras Alfraih and Al-Khabori, {Murtadha K.} and Mohsen Alzahrani and Ahmad Alhuraiji and Abdulaziz Hamadah and AlJohani, {Naif I.} and Bader Alahmari and Essa, {Mohammed F.} and Motabi, {Ibraheem H.} and Tailor, {Imran K.} and Almaghrabi, {Reem S.} and Khalil Al-Farsi and Ibraheem Abosoudah and Mouhab Ayas and Elhassan, {Tusneem A.} and Suhebeh, {Ashraf M.} and Ahmed, {Syed Osman} and Saud Alhayli and Panayotis Kaloyannidis and Ahmad Alsaeed and Anezi, {Khalid Al} and Sameer Alamoudi and Moussab Damlaj and Hashmi, {Hani Al} and Mahmoud Aljurf",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2021",

month = sep,

day = "1",

doi = "10.1038/s41409-021-01312-y",

language = "English",

volume = "56",

pages = "2144--2151",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East

AU - El Fakih, Riad

AU - Haroon, Alfadil

AU - Alfraih, Feras

AU - Al-Khabori, Murtadha K.

AU - Alzahrani, Mohsen

AU - Alhuraiji, Ahmad

AU - Hamadah, Abdulaziz

AU - AlJohani, Naif I.

AU - Alahmari, Bader

AU - Essa, Mohammed F.

AU - Motabi, Ibraheem H.

AU - Tailor, Imran K.

AU - Almaghrabi, Reem S.

AU - Al-Farsi, Khalil

AU - Abosoudah, Ibraheem

AU - Ayas, Mouhab

AU - Elhassan, Tusneem A.

AU - Suhebeh, Ashraf M.

AU - Ahmed, Syed Osman

AU - Alhayli, Saud

AU - Kaloyannidis, Panayotis

AU - Alsaeed, Ahmad

AU - Anezi, Khalid Al

AU - Alamoudi, Sameer

AU - Damlaj, Moussab

AU - Hashmi, Hani Al

AU - Aljurf, Mahmoud

PY - 2021/9/1

Y1 - 2021/9/1

N2 - The coronavirus disease‐2019 (COVID‐19) caused by SARS Coronavirus 2 (SARS‐CoV‐2) is a potentially lethal infection. Cancer patients, and specifically hematopoietic cell transplant (HCT) recipients are severely immunocompromised and may be at a higher risk of a complicated course with this infection. We aimed to study the COVID-19 outcomes and severity in post HCT patients. We retrospectively reviewed post-HCT patients diagnosed with COVID-19 between March 15, 2020, and December 1, 2020 at 10 transplant centers across the Middle East. We identified 91 patients with confirmed SARS-CoV-2 infection across 10 transplant centers. The median age upon presentation with COVID-19 was 35. Fifty two patients were post allo-HCT while the remaining 39 patients were post auto-HCT. The median time from transplant was 14.9 months. Mortality rate was 4.4%. Hospital admission rate was 53%. ICU admission rate was 14%. Mechanical ventilation rate was 10%. Oxygen supplementation rate was 18%. Time from HCT to COVID-19 >6 months was associated with lower admission rates and lower rates of the “severity” composite endpoint. Antibody responses was seen 67% of evaluable patients. In this series of HCT recipients, we report overall favorable clinical outcomes for patients with COVID-19 and provide preliminary insights into the clinical course of this disease in this specific population.

AB - The coronavirus disease‐2019 (COVID‐19) caused by SARS Coronavirus 2 (SARS‐CoV‐2) is a potentially lethal infection. Cancer patients, and specifically hematopoietic cell transplant (HCT) recipients are severely immunocompromised and may be at a higher risk of a complicated course with this infection. We aimed to study the COVID-19 outcomes and severity in post HCT patients. We retrospectively reviewed post-HCT patients diagnosed with COVID-19 between March 15, 2020, and December 1, 2020 at 10 transplant centers across the Middle East. We identified 91 patients with confirmed SARS-CoV-2 infection across 10 transplant centers. The median age upon presentation with COVID-19 was 35. Fifty two patients were post allo-HCT while the remaining 39 patients were post auto-HCT. The median time from transplant was 14.9 months. Mortality rate was 4.4%. Hospital admission rate was 53%. ICU admission rate was 14%. Mechanical ventilation rate was 10%. Oxygen supplementation rate was 18%. Time from HCT to COVID-19 >6 months was associated with lower admission rates and lower rates of the “severity” composite endpoint. Antibody responses was seen 67% of evaluable patients. In this series of HCT recipients, we report overall favorable clinical outcomes for patients with COVID-19 and provide preliminary insights into the clinical course of this disease in this specific population.

UR - http://www.scopus.com/inward/record.url?scp=85105164372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105164372&partnerID=8YFLogxK

U2 - 10.1038/s41409-021-01312-y

DO - 10.1038/s41409-021-01312-y

M3 - Article

C2 - 33907304

AN - SCOPUS:85105164372

SN - 0268-3369

VL - 56

SP - 2144

EP - 2151

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 9

ER -

Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this